Omar Bari, MD
Dermatology · Oklahoma City, OKNPI 1467958785
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Verrica Pharmaceuticals Inc. at 59.1% of the total. 2025 is the largest year on record at $5,897, more than ten times the $249 reported in 2019.
Across 54 payments — averaging $153.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Verrica Pharmaceuticals Inc.$5K
- AbbVie$830
- Arcutis Biotherapeutics, Inc.$402
- Galderma Laboratories, L.p.$307
- E.r. Squibb & Sons, L.L.C.$303
- Sanofi$273
- plus $1K from 10 others
What the payments were for
- Speaking & faculty fees$4,50054%
- Travel & lodging$360%
- Food & beverage$3,76545%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Verrica Pharmaceuticals Inc. | 10 | $4,916 |
| AbbVie | 8 | $830 |
| Arcutis Biotherapeutics, Inc. | 5 | $402 |
| Galderma Laboratories, L.p. | 7 | $307 |
| E.r. Squibb & Sons, L.L.C. | 6 | $303 |
| Sanofi | 3 | $273 |
| Stemline Therapeutics Inc. | 2 | $248 |
| Amgen | 2 | $225 |
| Incyte Corporation | 3 | $188 |
| Johnson & Johnson | 1 | $147 |
| Janssen Scientific Affairs, LLC | 1 | $141 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| UCB, Inc. | 1 | $102 |
| Lilly USA, LLC | 2 | $46 |
| Novartis | 1 | $33 |
| LEO Pharma Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,311 in reported general payments places this provider in the 70th percentile of 114 dermatology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 24 | $473,204 |
| Dupixent PenDupilumab | 33 | $169,039 |
| Humira(Cf) PenAdalimumab | 14 | $163,973 |
| Tacrolimus | 50 | $6,488 |
| Clindamycin Phosphate | 34 | $1,560 |
| Triamcinolone Acetonide | 76 | $1,295 |
| Clobetasol Propionate | 25 | $1,090 |
| Fluocinonide | 26 | $1,063 |
| Ketoconazole | 60 | $990 |
| Fluorouracil | 14 | $984 |
| Doxycycline Monohydrate | 17 | $353 |
| Hydrocortisone | 38 | $249 |
| Minoxidil | 13 | $82 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Oklahoma City
- Yaohan LamOklahoma City$88K
- Kimberly JerdanOklahoma City$59K
- Mark DawkinsOklahoma City$56K
- Quy PhamOklahoma City$14K
- Sunita CrittendenOklahoma City$13K
- Tiffany BrazealOklahoma City$13K
- Robert LehrOklahoma City$11K
- Courtney CookOklahoma City$10K
- Clifford HendersonOklahoma City$9K
- Roy RindlerOklahoma City$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.